JOURNAL ARTICLE

Moderna Inc.

  • Published In: Corporate Philanthropy Report, 2023, v. 38, n. 1. P. 6 1 of 2

  • Database: Business Source Ultimate 2 of 2

Abstract

B Moderna Inc. b 200 Technology Square Cambridge, MA 02139 https://www.modernatx.com, (866) 663 3762 OVERVIEW Moderna is a leading biotechnology company known for pioneering messenger RNA therapeutics and vaccines - including one of the earliest approved vaccines for the virus that causes COVID-19 - aimed at improving the lives of patients. The company offers therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and autoimmune diseases; owns a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation; and operates an integrated manufacturing plant that allows for rapid clinical and commercial production at scale. Moderna and its foundation are partnering with the IRC to support infection prevention and control programs in West and Central Africa, particularly in countries that have been impacted by conflict. [Extracted from the article]

Additional Information

  • Source:Corporate Philanthropy Report. 2023/01, Vol. 38, Issue 1, p6
  • Document Type:Article
  • Subject Area:Business and Management
  • Publication Date:2023
  • ISSN:0885-8365
  • DOI:10.1002/cprt.31477
  • Accession Number:160716535
  • Copyright Statement:Copyright of Corporate Philanthropy Report is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Looking to go deeper into this topic? Look for more articles on EBSCOhost.